{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T17:37:33Z","timestamp":1720978653909},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2012,3,21]],"date-time":"2012-03-21T00:00:00Z","timestamp":1332288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Spine J"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s00586-012-2231-1","type":"journal-article","created":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T09:07:19Z","timestamp":1332234439000},"page":"141-145","source":"Crossref","is-referenced-by-count":6,"title":["Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses: preliminary report"],"prefix":"10.1007","volume":"21","author":[{"given":"Francesco C.","family":"Tamburrelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Scaramuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. A.","family":"Logroscino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,21]]},"reference":[{"key":"2231_CR1","first-page":"291","volume":"13","author":"GR Mundy","year":"1986","unstructured":"Mundy GR, Bertoline DR (1986) Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 13:291\u2013299","journal-title":"Semin Oncol"},{"key":"2231_CR2","doi-asserted-by":"crossref","first-page":"6279s","DOI":"10.1158\/1078-0432.CCR-06-0681","volume":"12","author":"HS Yeh","year":"2006","unstructured":"Yeh HS, Berenson JR (2006) Treatment for myeloma bone disease. Clin Cancer Res 12:6279s\u20136284s","journal-title":"Clin Cancer Res"},{"key":"2231_CR3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","volume":"23","author":"GD Rodmann","year":"2009","unstructured":"Rodmann GD (2009) Pathogenesis of myeloma bone diseases. Leukemia 23:435\u2013441","journal-title":"Leukemia"},{"key":"2231_CR4","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","volume":"63","author":"RE Marx","year":"2005","unstructured":"Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567\u20131575","journal-title":"J Oral Maxillofac Surg"},{"key":"2231_CR5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.seminoncol.2003.08.017","volume":"30","author":"L Lacerna","year":"2003","unstructured":"Lacerna L, Hohneker J (2003) Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. Semin Oncol 30:150\u2013160","journal-title":"Semin Oncol"},{"key":"2231_CR6","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","volume":"20","author":"JR Berenson","year":"2002","unstructured":"Berenson JR, Hillner BE, Kyle RA et al (2002) American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20:3719\u20133736","journal-title":"J Clin Oncol"},{"key":"2231_CR7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s005200100292","volume":"10","author":"JJ Body","year":"2002","unstructured":"Body JJ, Mancini I (2002) Bisphosphonates for cancer patients: why, how and when? Support Care Cancer 10:399\u2013407","journal-title":"Support Care Cancer"},{"issue":"6","key":"2231_CR8","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s001130170111","volume":"104","author":"C Knop","year":"2001","unstructured":"Knop C, Oeser M, Bastian L, Lange U, Zdichavsky M, Blauth M (2001) Development and validation of the visual analogue scale (VAS) spine score. Unfallchirurg 104(6):488\u2013497","journal-title":"Unfallchirurg"},{"key":"2231_CR9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organitation for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials oncology. J Natl Cancer Inst 85:365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"2231_CR10","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/annonc\/mdi235","volume":"16","author":"E Terpos","year":"2005","unstructured":"Terpos E, Dimopoulos MA (2005) Myeloma bone disease pathophisiology and management. Ann Oncology 16:1223\u20131231","journal-title":"Ann Oncology"},{"key":"2231_CR11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2141.2004.05084.x","volume":"126","author":"F Silvestris","year":"2004","unstructured":"Silvestris F, Cafforio P, Calvani N, Dammacco F (2004) Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol 126:475\u2013486","journal-title":"Br J Haematol"},{"key":"2231_CR12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1365-2141.2002.03824.x","volume":"119","author":"S Gordon","year":"2002","unstructured":"Gordon S, Helfrich MH, Sati HI et al (2002) Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br J Haematol 119:475\u2013483","journal-title":"Br J Haematol"},{"key":"2231_CR13","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","volume":"18","author":"PI Croucher","year":"2003","unstructured":"Croucher PI, De Hendrik R, Perry MJ et al (2003) Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 18:482\u2013492","journal-title":"J Bone Miner Res"},{"key":"2231_CR14","unstructured":"Savage AD, Belson DJ, Vesico RA et al (1996) Pamidronate reduces IL-6 production by bone marrow stroma from myeloma patients. Blood 88:105A"},{"key":"2231_CR15","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1359\/jbmr.1999.14.12.2048","volume":"14","author":"S Derenne","year":"1999","unstructured":"Derenne S, Amiot M, Barille S et al (1999) Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 14:2048\u20132056","journal-title":"J Bone Miner Res"},{"key":"2231_CR16","unstructured":"Djulbegovic B, Wheatley K, Ross J et al (2002) Bisphosphonates in multiple myeloma (Cochrane Review). Cochrane Database Syst Rev 3:CD003188"},{"key":"2231_CR17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1046\/j.1365-2141.2001.03206.x","volume":"115","author":"British Committee for Standards in Haematology (UK Myeloma Forum)","year":"2001","unstructured":"British Committee for Standards in Haematology (UK Myeloma Forum) (2001) Diagnosis and management of multiple myeloma. Br J Haematol 115:522\u2013540","journal-title":"Br J Haematol"},{"key":"2231_CR18","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1345\/aph.1E357","volume":"39","author":"AA Licata","year":"2005","unstructured":"Licata AA (2005) Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 39:668\u2013677","journal-title":"Ann Pharmacother"},{"key":"2231_CR19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/17453670610046361","volume":"77","author":"N Hansen-Algenstaedt","year":"2006","unstructured":"Hansen-Algenstaedt N, Johschek C, Wolfram L et al (2006) Sequential changes in vessel formation and micro-vascular function during bone repair. Acta Orthop 77:429\u2013439","journal-title":"Acta Orthop"},{"key":"2231_CR20","first-page":"15","volume":"3","author":"MA Sabino","year":"2005","unstructured":"Sabino MA, Mantyh PW (2005) Pathophysiology of bone cancer pain. J Support Oncol 3:15\u201324","journal-title":"J Support Oncol"},{"key":"2231_CR21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3816\/CLC.2004.n.030","volume":"6","author":"V Hirsh","year":"2004","unstructured":"Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei YJ (2004) Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 6:170\u2013174","journal-title":"Clin Lung Cancer"},{"key":"2231_CR22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ncponc1323","volume":"6","author":"L Costa","year":"2009","unstructured":"Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Prat Oncol 6:163\u2013174","journal-title":"Nat Clin Prat Oncol"},{"key":"2231_CR23","doi-asserted-by":"crossref","unstructured":"Terpos E, Sezer O, Croucher PI et al (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20:1303\u20131317","DOI":"10.1093\/annonc\/mdn796"}],"container-title":["European Spine Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00586-012-2231-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00586-012-2231-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00586-012-2231-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T21:13:05Z","timestamp":1561497185000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00586-012-2231-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,21]]},"references-count":23,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["2231"],"URL":"https:\/\/doi.org\/10.1007\/s00586-012-2231-1","relation":{},"ISSN":["0940-6719","1432-0932"],"issn-type":[{"value":"0940-6719","type":"print"},{"value":"1432-0932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,21]]}}}